ecancertv Videos
ASCO 2009: Maintenance therapy for NSCLC
Dr. Vincent A. Miller - MD Memorial Sloan-Kettering Cancer Center, New York, USA ASCO press conference: A phase III trial finds that adding erlotinib (Tarceva) to bevacizumab-based (Avastin) maintenance therapy in patients with advanced NSCLC delays cancer progression more than maintenance treatment with bevacizumab alone.
ASCO 2009: Patient accrual in clinical trials
Steven K. Cheng, phd - Oregon Health and Science University, Oregan, USA. ASCO press conference: New research shows that the longer it takes to develop a cancer clinical trial, the less likely it is that the trial will meet its goal for accruing patients and the less able it will be to report a statistically significant result.
ASCO 2009: Experimental targeted therapy improves progression-free survival for advanced NSCLC
Dr Roy Herbst, MD Anderson Cancer Center, Houston, US ASCO 2009: Experimental Targeted Therapy Vandetanib Improves Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer The results of an international trial have shown that adding the experimental targeted therapy vandetanib (Zactima) to docetaxel improves progression-free survival in patients with advanced non-small cell lung cancer (NSCLC) whose disease has progressed after first-line treatment. This is the first ...
ASCO 2009: Oestrogen and progestin therapy increases NSCLC risk
ASCO 2009: Rowan T. Chlebowski, MD, phd - Harbor-UCLA Medical Center - Los Angeles: Menopausal Hormone Therapy with Estrogen and Progestin Linked to Increased Risk of Death from Non-Small Cell Lung Cancer Researchers have shown that use of hormone therapy with estrogen plus progestin increases the risk of dying from non-small cell lung cancer (NSCLC) in women with the disease. Lung cancer is the leading cause of cancer death in US women.
ASCO 2009: Lung cancer patients lacking MSH2 DNA repair protein fare better with chemo
Pierre Fouret, MD, phd, Institut Gustave Roussy, Université Pierre et Marie Curie, Paris, France: Speaking at ASCO 2009: Lung Cancer Patients Lacking MSH2 DNA Repair Protein Fare Better with Chemotherapy: An analysis from the International Adjuvant Lung Trial (IALT) reports that tumor levels of the MSH2 protein predict long-term response to cisplatin-based chemotherapy among patients with surgically removed non-small cell lung cancer (NSCLC). MSH2 is a protein that cancer cells use to repair ...
ACSO 2009: Dr Patrick Hwu
ACSO 2009: Therapeutic vaccine improves response rate and extends progression-free survival in patients with metastatic melanoma Patrick Hwu, MD, Chair of the Department of Melanoma Medical Oncology MD Anderson Cancer Center: Therapeutic Vaccine Improves Response Rate and Extends Progression-Free Survival in Patients with Metastatic Melanoma: Preliminary findings from a phase III, multicenter trial show that adding a novel cancer vaccine called gp100:209-217(210M) peptide to standard therapy ...
ASCO 2009: Bevacizumab and standard adjuvant chemotherapy
ASCO 2009: Bevacizumab and standard adjuvant chemotherapy: no improvement in disease-free survival for early-stage colon cancer. Dr Norman Wolmark - Chairman Dept of Human Oncology, Allegheny General Hospital, US ASCO press conference: Adding bevacizumab (avastin) to standard adjuvant chemotherapy does not improve disease-free survival for early-stage colon cancer
ASCO 2009: PARP inhibitor BS-201 plus chemotherapy: new option for triple-negative breast cancer
Joyce oshaughnessy, MD, Baylor-Charles A. Sammons Cancer Center, Dallas, Texas, speaking at ASCO 2009: PARP Inhibitor BS-201 Plus Chemotherapy May Offer New Treatment Option for Triple-Negative Breast Cancer: A randomized Phase II study, featured in ascos plenary session, shows that women with metastatic triple-negative breast cancer who received the investigationalparp inhibitor BSI-201, in combination with conventional chemotherapy, lived significantly longer and experienced significantly ...
Tags: q0g JoyceOshaugnessyA
